Update notification · 24.08.2026
Supply shortage Germany: ZYPADHERA 210 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension
Affected country: Germany · Reported period: 26.08.2026 – 09.12.2026 · Active ingredient: Olanzapinembonat-Monohydrat
Notice context
A supply shortage has been recorded for ZYPADHERA 210 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension in Germany. The stated reason is “Manufacturing problems”. The notice concerns the active ingredient Olanzapinembonat-Monohydrat and is identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Germany. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for ZYPADHERA 210 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension is a supply signal concerning Olanzapinembonat-Monohydrat in Germany. The published reason “Manufacturing problems” determines which data should be verified first.
Because the published reason does not establish a reliable operational cause, availability, source, timing, product status and the supply route should be verified without adding an unsupported explanation.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess source, product status, timing, lawful sourcing route and any buffer stock without adding an unsupported cause.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
A resilient stock concept for ZYPADHERA 210 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension requires prior verification of product status, demand, coverage and the permitted supply route.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Because the product name may indicate a temperature-sensitive dosage form, the product specification and any 2–8 °C requirement are assessed project by project; this is not a blanket capacity commitment.
Operational checks for this notice
- Match product identity using PZN 07373247, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 26.08.2026 to 09.12.2026 with the primary source and potential suppliers.
- Prioritise hospital demand, supply relevance and the escalation route with the accountable market participants.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving ZYPADHERA 210 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension: